(Reuters) -China's Zhifei will pay GSK about 2.3 billion pounds ($2.9 billion) for the exclusive rights to distribute GSK's shingles vaccine in China, the UK drugmaker said on Thursday, lower than ...

GSK is enlisting the aid of China’s Chongqing Zhifei Biological Products (Zhifei) to drive sales of its most important vaccine, Shingrix, in China over the next few years, and may also call upon ...

GSK PLCGSK0.41%increase; green up pointing triangle extended its collaboration with Chongqing Zhifei Biological Products 300122-0.18%decrease; red down pointing triangle to commercialize its ...

(RTTNews) - GSK plc (GSK, GSK.L), on Thursday, said it has agreed with Chongqing Zhifei Biological Products Ltd. to revise the terms on which Zhifei will commercialize GSK's shingles vaccine ...

GSK inked an antibody-drug conjugate deal with DualityBio and, through a revised agreement with Zhifei, dialed down its expectations for Shingrix in China for the next few years. And more.

INR:1974. beautiful indian women's cricket team names with photos Zhifei Bio's Rotavirus Inactivated Vaccine Obtains Clini ...

INR:5374. india squad for england Daratumumab injection (subcutaneous injection) was approved for marketing approval in China Zhifei Bio's COVID-19 vaccin ...

Revised deal with Zhifei to manage near-term challenges GSK shares marginally lower Potential RSV collaboration for initial 10-year term Dec 5 (Reuters) - China's Zhifei (300122.SZ), opens new tab ...

GSK PLC extended its collaboration with Chongqing Zhifei Biological Products to commercialize its shingles vaccine Shingrix in China until 2034. The British pharma company said Thursday that it ...

GSK plc announced that it has entered into an agreement with Chongqing Zhifei Biological Products, Ltd. (Zhifei) to revise the terms on which Zhifei will commercialise GSK’s shingles vaccine, Shingrix ...